Evidence map›Paper›PMID 42245639›Full record

ArticleFrontiers in immunology2026

Unmasking the "targetless" illusion: branched clonal evolution of

Yuqiao Fu, Peng Li, Ke Li, Lei Jiang, Yingzi Liang, Lipei Shao, Ya Zhang, Chunlei Ge, Zhaoqi Zhang, Ying Wang and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuqiao Fu *Cancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Peng Li *Science and Technology Achievement Transformation Center, Kunming Medical University, Kunming, China.
Ke Li *Cancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Lei JiangCancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Yingzi LiangCancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Lipei ShaoDepartment of Cell Biology, Nanjing Medical University, Nanjing, China.
Ya ZhangDepartment of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Chunlei GeCancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Zhaoqi ZhangCancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Ying WangCancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
Ruilei LiCancer Biotherapy Center & Cancer Research Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor clonal evolution and spatiotemporal heterogeneity are key drivers of therapeutic resistance in melanoma, often driven by selection pressures generated by systemic therapy. Genetic testing plays a key role in guiding targeted therapies, but a single biopsy may not fully reflect the mutational landscape. This paper reports a case of metastatic acral melanoma that demonstrated dynamic branching clonal evolution under systemic therapeutic stress. The patient first underwent genetic testing in 2022. A 168-gene panel performed on a newly developed inguinal lymph node metastasis revealed only a

Indexed as

Clonal EvolutionMelanomaProto-Oncogene Proteins c-kitSkin NeoplasmsTelomeraseBiopsyHumansMutationKIT protein, humanProto-Oncogene Proteins c-kitTelomeraseTERT protein, humanacral melanomabranched clonal evolutionKIT p.Ala829Prospatiotemporal heterogeneitysystemic therapeutic pressureTERT promoter mutation

Identifiers

PMID42245639
PMCPMC13230091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.